Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) EVP David Hallal sold 1,620 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $155.57, for a total value of $252,023.40. Following the transaction, the executive vice president now directly owns 113,965 shares of the company’s stock, valued at approximately $17,729,535. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 3.96% during mid-day trading on Monday, hitting $170.11. The stock had a trading volume of 2,359,160 shares. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $171.09. The stock’s 50-day moving average is $140.5 and its 200-day moving average is $121.6. The company has a market cap of $33.415 billion and a P/E ratio of 128.84.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings data on Thursday, January 30th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.04. The company had revenue of $441.90 million for the quarter, compared to the consensus estimate of $430.08 million. On average, analysts predict that Alexion Pharmaceuticals will post $3.87 earnings per share for the current fiscal year.

ALXN has been the subject of a number of recent research reports. Analysts at Deutsche Bank raised their price target on shares of Alexion Pharmaceuticals from $125.00 to $205.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Separately, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday. They now have a $189.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, February 4th. They now have a $170.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and fourteen have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $159.61.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.